ClinicalTrials.gg
RecruitingNCT07316153Updated Nov 16, 2026

Deep Sleep in Older Adults

A Phase 2 interventional study of SleepSpaceRx CBT-I-IoT-AI and SleepEZ CBTi in Insomnia and Insomnia Chronic, sponsored by Proactive Life Inc. Recruiting at 2 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Proactive Life Inc · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 16, 2026Now RecruitingEligibility revised+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 149 open to participants now, 186 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.

Planned enrollment
164th of 858
180 · median 60
Started
2026
with 60 others
Phase 2
83 of 907
15 open now
Primary completion
2027-08
later than 108 of 185 live
Registered
847th of 907
by date

Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 164th largest by planned enrollment of the 858 interventional ones that give a count, is one of 61 that started in 2026, is one of 83 in phase 2, reaches primary completion later than 108 of the 185 other live ones, and was the 847th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

149 of the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 149 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, or all of them as a file.
02

Study summary

This double blind randomized clinical trial on older independent-living healthy individuals with symptoms of insomnia will harness Cognitive Behavioral Therapy for Insomnia (CBT-I) and augment it with ambulatory data collection devices, personalized digital content, and smart sound and light cues (CBT-I +Internet of Things [IoT]+Artificial Intelligence [AI]). With this approach, the investigators aim to overcome many of the limitations that CBT-I in the clinic faces: the investigators can implement it in ambulatory settings while providing increased (remote) accessibility to therapy. The investigators will compare the CBT-I +IoT+AI to active controls that also integrate with smart phone devices, including SleepEZ, which is also based on CBT-I, and sleep hygiene education. These active controls will help determine whether CBT-I +IoT+AI is effective at treating insomnia based on the Insomnia Severity Index (ISI) (primary outcome), sleep metrics (secondary outcome), cognitive performance (secondary outcome), and additional outcomes like therapeutic adherence and other mental health assessments. Participants will be asked to track sleep with wearable and nearable devices, complete surveys, and complete cognitive assessments.

Read the detailed description

Insomnia is highly prevalent in older adults and is associated with impaired daytime functioning and increased risk for cognitive decline. Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended first-line treatment, yet access, adherence, and scalability remain persistent barriers, particularly for older populations. Digital CBT-I programs address some access challenges but often demonstrate reduced adherence and diminished effectiveness in real-world use.

This study evaluates a fully remote, automated digital CBT-I system that integrates mobile software with Internet of Things (IoT)-enabled environmental cues and artificial intelligence-driven personalization. The intervention is designed to promote adherence to CBT-I principles by passively supporting sleep-wake routines using adaptive sound, light, and behavioral prompts delivered through consumer electronic devices in the participant's home environment.

The study is a randomized, double-blind, controlled trial conducted entirely remotely in community-dwelling older adults with clinically significant insomnia symptoms. Following screening and baseline assessment, participants are randomly assigned in a 1:2:2 allocation to one of three study arms: 1) SleepSpaceRx CBT-I-IoT-AI (n=72), 2) Sleep-EZ CBT-I-based active comparator (n=72), or 3) Sleep Hygiene + IoT active comparator (n=36). All participants receive comparable study devices and interaction time to maintain blinding and control for expectancy effects.

The intervention period lasts six weeks and is preceded by a baseline assessment phase and followed by post-intervention and follow-up assessments. Throughout the study, participants complete standardized self-report measures of insomnia severity and engage in repeated, brief cognitive assessments administered via mobile devices. Objective sleep data are collected using non-invasive, ambulatory sensing technologies that operate passively in the home environment.

The primary objective of the study is to compare changes in insomnia severity across study arms. Secondary objectives include evaluation of sleep characteristics, adherence to behavioral recommendations, and performance on cognitive tasks sensitive to sleep-related changes in older adults. The study is designed to assess feasibility, usability, and preliminary efficacy of an automated, home-based digital CBT-I approach that emphasizes adherence support and sleep quality enhancement.

This trial will contribute evidence on whether an integrated digital and IoT-based behavioral intervention can improve insomnia outcomes and support cognitive functioning in older adults, informing future large-scale trials and potential clinical implementation.

03

Conditions studied

  • Insomnia
  • Insomnia Chronic

Keywords

  • cognitive behavioral therapy
  • internet of things
  • wearables
  • insomnia
  • older adults
  • cognitive impairment
  • cognition
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fluent English speaker and reader.
  2. Capable of providing one's own . a. As determined by validated, abbreviated phone-based remote (MoCA) testing score of ≥18, which is the score that separates Mild Cognitive Impairment (MCI) from Alzheimer's Disease and Related Dementia (ADRD).
  3. Age 55+ years old (inclusive) at enrollment. a. As self-reported on screening survey and later verified in video appointment (e.g. Zoom Health)
  4. If residing in a community residence (such as a retirement community) in which a Medical Director designates living status categories, then the participant must be Independent Living status (or equivalent).

    a. As self-reported on screening survey

  5. Insomnia Severity Index score ≥15 (i.e., at least "clinical insomnia," that is "moderate-to-severe") - but if recruitment is slow then the investigators will recruit with ISI score ≥11 "mild-to-severe").

    a. As self-reported on the ISI screening survey

  6. Willing to refrain from initiating new therapeutic interventions (e.g. medication; behavioral) that are not a part of this study protocol for issues pertaining to sleep for the duration of study participation.

    1. By self-report
  7. Willing to maintain any existing physician-directed pharmacologic intervention for issues pertaining to sleep for the duration of study participation.

    a. By self-report

  8. Has a residence with WIFI. a. By self-report
  9. Difficulty falling asleep, staying asleep, or waking too early, occurring at least 3 nights/week for 3+months, causing significant daytime distress/impairment (e.g., fatigue, poor focus, mood issues), despite adequate sleep opportunity, and not better explained by another sleep disorder or substance.

    1. By Sleep Condition Indicator [SCI]

Exclusion criteria

Exclusion Criteria

  1. Illicit drug use in the past month (except for marijuana because it is legal in many States, and the investigators are recruiting nationwide).

    a. As self-reported on screening survey. Marijuana usage will be tracked via self-report and examined as a moderator.

  2. Diagnosed serious mental health disorder.

    1. Specifically, psychosis or bipolar depression, severe major depression, moderate to high risk of suicide, dementia
    2. As self-reported on screening survey
  3. Currently or recent engaged (past 1-year) in evidence-based psychotherapy for Insomnia (e.g., CBTi), in addition to ever receiving a full course of CBTi:

    a. By self-report

  4. Cohabitating with a current or previous participant in this study.

    a. This criterion is to avoid cross-contamination of study condition awareness, if two cohabitating individuals are randomized into different study arms.

  5. Initiation of any psychological treatment in the last 3-months.
  6. A highly irregular schedule (e.g. shift work) that would prevent adoption of intervention strategies, as evaluated through the Shift Work Disorder Index.
  7. Previous exposure to the SleepSpace software.
  8. Medical conditions that are exacerbated by sleep restriction.
  9. Planned major surgery during the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    SleepSpaceRx CBT-I-IoT-AI

    Participants randomized to this study arm will experience an attempted enhancement of standard video based digital CBT-I, that is facilitated with electronic device-based interventions (Internet of Things) and artificial intelligence (AI) customizations of content. Noninvasive ambulatory worn + bedside devices deliver real-time feedback of objective data to the participant on an application interface and this data is used to customize the software and promote healthy sleep routines. In addition, daily animated videos are customized to the users' challenges. Subjective data collected using the application are available live to the participant, when appropriate. Environmental cues and notifications are programmed into IoT devices to remind patients of their behavioral prescription and to create a living-space environment that is conducive to effective therapy. This will include smart lights and sounds that cue the participant.

    Behavioral: SleepSpaceRx CBT-I-IoT-AI

  • Active comparator
    Sleep-EZ CBT-I Based Solution

    Participants randomized to this study arm will experience standard digital-based CBT-I that is delivered via the Path to Better Sleep program called SleepEZ that was created by Veteran Affairs (VA). The program will be administered within the SleepSpace software, which will be used to track adherence and deliver sham interventions. Users will have access to a pared-down version of the SleepSpace electronic application that enables them to track sleep in a sleep diary, access the content found in SleepEZ, and integrate with smart light bulbs and sounds to receive certain sound and light interventions. For example, the lights will brighten during the users expected circadian dip.

    Behavioral: SleepEZ CBTi

  • Active comparator
    Sleep Hygiene + IoT

    Participants randomized to this study arm will experience sleep hygiene education and training, a component of CBT-I, which will also occur within the SleepSpace software to ensure all participants receive the same software platform and adherence is tracked uniformly across solutions. Users will have access to a version of our electronic application that enables them to track sleep in a sleep diary, access the animated Sleep Hygiene content created in the same way as the videos in the CBTi-IoT-AI condition, and integrate with smart light bulbs and sounds to receive certain sound and light interventions.

    Behavioral: Sleep Hygiene IoT

Interventions

  • BehavioralSleepSpaceRx CBT-I-IoT-AI

    What distinguishes this condition is increased customization of the CBT-I content and increased usage of the Internet of Things (IoT) devices used to promote CBT-I directives.

  • BehavioralSleepEZ CBTi

    This condition includes interactive videos about CBT-I and leverages some IoT interventions.

  • BehavioralSleep Hygiene IoT

    This intervention includes interactive videos regarding sleep hygiene, a component of CBT-I and leverages some IoT interventions.

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index (ISI)

    Subjective patient completion of the Insomnia Severity Index survey. Sum of survey item responses; Minimum score: 0; Maximum score: 28. Higher sum score indicates a greater number of, or more severe, insomnia symptoms; reduction in sum score suggests improvement of insomnia.

    Time frame: Weekly for the first 8 weeks, then at week 10 and week 12

Secondary outcomes

  1. Change in cognitive test battery performance

    Objective test performance metrics on an ambulatory cognitive test battery delivered with a smartphone device that includes validated assessments: the Mobile Monitoring of Cognitive Change (M2C2) and DANA Brain Vitals.

    Time frame: M2C2 is Daily during Baseline Weeks 1-2 and post-intervention Weeks 9-10. and Dana is Daily during Baseline Week 2 and post-intervention Week 10.

  2. Consensus Sleep Diary

    Subjective sleep diary data will be used to determine perceived sleep features (duration, quality, time in bed, etc).

    Time frame: Time Frame: Daily during Baseline Weeks 1-2, Intervention Weeks 3-8, and post-intervention Weeks 9-10.

Other outcomes

  1. Nearable Sleep Sensing (Motion)

    Motion (up to 50 hertz x, y, z actigraphy) from the iPhone will be used to estimate time in bed, sleep/wake, sleep onset latency, wake after sleep onset, and other sleep related metrics.

    Time frame: Daily from week two to week eight

  2. Nearable Sleep Sensing (Sound)

    Sound data (decibels) from the iPhone will be used to estimate time in bed, sleep/wake, sleep onset latency, wake after sleep onset, and other sleep related metrics.

    Time frame: Daily from week two to week eight

  3. Wearable Sleep Sensing (Motion)

    Motion (up to 50 hertz x, y, z actigraphy) from the Apple Watch or Sensor Bio wearable will be used to estimate time in bed, sleep/wake, sleep onset latency, wake after sleep onset, and other sleep related metrics.

    Time frame: Daily during Baseline to Week 2 (randomization) and the post-intervention assessment period (Weeks 9-10).

  4. Wearable Sleep Sensing (Heart Rate)

    Heart rate (up to .2 hertz) from the Apple Watch or Sensor Bio wearable will be used to estimate time in bed, sleep/wake, sleep onset latency, wake after sleep onset, and other sleep related metrics.

    Time frame: Daily during Baseline to Week 2 (randomization) and the post-intervention assessment period (Weeks 9-10).

  5. Adherence

    The frequency and duration of engagement with the content or other active aspects of the intervention

    Time frame: Daily during the intervention: Week three to Week eight

  6. Generalized Anxiety Symptoms

    Change in anxiety symptoms measured by the Generalized Anxiety Disorder 7 item scale (GAD 7).

    Time frame: Baseline (Week 1) to post treatment (Week 12)

  7. Depressive Symptoms

    Change in depressive symptoms measured by the Patient Health Questionnaire 8 item scale (PHQ 8).

    Time frame: Baseline (Week 1) to post treatment (Week 12)

  8. Post Traumatic Stress Symptoms

    Change in post traumatic stress symptoms measured by the Primary Care PTSD Screen (PC PTSD).

    Time frame: Baseline (Week 1) to post treatment (Week 12)

  9. Social Connectedness From Voice Features

    Exploratory changes in social connectedness metrics derived from speech and voice features collected during study interactions.

    Time frame: Baseline (Week 1) to post treatment (Week 12)

07

Study locations

2 of 2 sites recruiting
  • SleepSpace
    New York, New York 10012, United States
    Recruiting
  • SleepSpace
    New York, New York 10012, United States
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

Of 27 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's planned 11 months is below that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Mar 2026 → Sep 2026, primary completion Dec 2026 → Aug 2027 and completion Dec 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 5, 2026
StartActual
Sep 30, 2026was Mar 2026
Primary completionEst.
Aug 30, 2027was Dec 2026
CompletionEst.
Aug 30, 2027was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
1 site added. SleepSpace is now Recruiting
Show site
  • SleepSpace · New York, United States
across 2 updates, Oct 2, 2026 – Oct 20, 2026
Start date
Mar 1, 2026→Sep 30, 2026
Oct 2, 2026
Primary completion
Dec 30, 2026→Aug 30, 2027
Oct 2, 2026
Study completion
Dec 30, 2026→Aug 30, 2027
Oct 2, 2026
Eligibility
Minimum age 65 Years→55 Years; Criteria revised in 2 updates
What changed on Oct 2, 2026
Inclusion criteria
  • RemovedAge 65+ years old (inclusive) at enrollment, but if recruitment is slow, the investigators may adjust the criteria to 60+, and if it is still slow, it could go as low as 55+ years old.
  • EditedAge 55+ years old (inclusive) at enrollment. a. As self-reported on screening survey and later verified in video appointment (e.g. Zoom Health)
What changed on Nov 16, 2026
Inclusion criteria
  • RemovedCapable of providing one's own informed consent.
  • EditedCapable of providing one's own informed consent. a. As determined by validated, abbreviated phone-based remote Montreal Cognitive Assessment (MoCA) testing score of ≥18, which is the score that separates Mild Cognitive Impairment (MCI) from Alzheimer's Disease and Related Dementia (ADRD).
  • EditedHas a residence with WIFI. a. By self-report
  • RemovedBy self-report
  • RemovedNormal hearing with or without a hearing aid.
  • RemovedBy self-report
across 2 updates, Oct 2, 2026 – Nov 16, 2026
Interventions
Changed CBT-I-IoT-AI→SleepSpaceRx CBT-I-IoT-AI. Arm changed CBT-I-IoT-AI→SleepSpaceRx CBT-I-IoT-AI
Oct 2, 2026
Secondary outcomes
4 time frame changed, 3 description edited
What changed in the outcomes
  • Time frameChange in cognitive test battery performanceDaily for two weeks at baseline and two weeks post treatment → M2C2 is Daily during Baseline Weeks 1-2 and post-intervention Weeks 9-10. and Dana is Daily during Baseline Week 2 and post-intervention Week 10.
  • Time frameConsensus Sleep DiaryDaily for the first eight weeks of the trial → Time Frame: Daily during Baseline Weeks 1-2, Intervention Weeks 3-8, and post-intervention Weeks 9-10.
  • Time frameother outcomeWearable Sleep Sensing (Motion)Daily from week two to week eight → Daily during Baseline to Week 2 (randomization) and the post-intervention assessment period (Weeks 9-10).
  • Time frameother outcomeWearable Sleep Sensing (Heart Rate)Daily from week two to week eight → Daily during Baseline to Week 2 (randomization) and the post-intervention assessment period (Weeks 9-10).
  • Descriptionother outcomeAdherence: how it is measured was reworded
  • Descriptionother outcomeWearable Sleep Sensing (Heart Rate): how it is measured was reworded
  • Descriptionother outcomeWearable Sleep Sensing (Motion): how it is measured was reworded
Oct 20, 2026
Contact
Study contact changed: m•••@sleepspace.com · •••1660→o•••@sleepspace.com · •••1660. See the current contact
Oct 2, 2026
Show all 3 updates
  1. Nov 16, 2026
    Eligibility 2 inclusion criteria edited, 4 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedCapable of providing one's own informed consent.
    • EditedCapable of providing one's own informed consent. a. As determined by validated, abbreviated phone-based remote Montreal Cognitive Assessment (MoCA) testing score of ≥18, which is the score that separates Mild Cognitive Impairment (MCI) from Alzheimer's Disease and Related Dementia (ADRD).
    • EditedHas a residence with WIFI. a. By self-report
    • RemovedBy self-report
    • RemovedNormal hearing with or without a hearing aid.
    • RemovedBy self-report
    + 2 other changes: verification date and date precision
  2. Oct 20, 2026
    SleepSpace is now Recruiting
    Secondary outcomes 4 time frame changed, 3 description edited
    What changed in the outcomes
    • Time frameChange in cognitive test battery performanceDaily for two weeks at baseline and two weeks post treatment → M2C2 is Daily during Baseline Weeks 1-2 and post-intervention Weeks 9-10. and Dana is Daily during Baseline Week 2 and post-intervention Week 10.
    • Time frameConsensus Sleep DiaryDaily for the first eight weeks of the trial → Time Frame: Daily during Baseline Weeks 1-2, Intervention Weeks 3-8, and post-intervention Weeks 9-10.
    • Time frameother outcomeWearable Sleep Sensing (Motion)Daily from week two to week eight → Daily during Baseline to Week 2 (randomization) and the post-intervention assessment period (Weeks 9-10).
    • Time frameother outcomeWearable Sleep Sensing (Heart Rate)Daily from week two to week eight → Daily during Baseline to Week 2 (randomization) and the post-intervention assessment period (Weeks 9-10).
    • Descriptionother outcomeAdherence: how it is measured was reworded
    • Descriptionother outcomeWearable Sleep Sensing (Heart Rate): how it is measured was reworded
    • Descriptionother outcomeWearable Sleep Sensing (Motion): how it is measured was reworded
    + 3 other changes: verification date, description and arm descriptions
  3. Oct 2, 2026
    Not yet recruiting→Recruiting
    1 site added. SleepSpace is now Not yet recruiting
    Show site
    • SleepSpace · New York, United States
    Start date Mar 1, 2026→Sep 30, 2026
    Primary completion Dec 30, 2026→Aug 30, 2027
    Study completion Dec 30, 2026→Aug 30, 2027
    Eligibility Minimum age 65 Years→55 Years; 1 inclusion criterion edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAge 65+ years old (inclusive) at enrollment, but if recruitment is slow, the investigators may adjust the criteria to 60+, and if it is still slow, it could go as low as 55+ years old.
    • EditedAge 55+ years old (inclusive) at enrollment. a. As self-reported on screening survey and later verified in video appointment (e.g. Zoom Health)
    Interventions Changed CBT-I-IoT-AI→SleepSpaceRx CBT-I-IoT-AI. Arm changed CBT-I-IoT-AI→SleepSpaceRx CBT-I-IoT-AI
    Contact Study contact changed: m•••@sleepspace.com · •••1660→o•••@sleepspace.com · •••1660. See the current contact
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07316153
Lead sponsor
Proactive Life Inc
Responsible party
Daniel Gartenberg (CEO, Proactive Life Inc) — Principal investigator
First posted
Jan 5, 2026
Start date
Sep 30, 2026
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Daniel Gartenberg, PhD
Contact
dan@sleepspace.com
732-668-1250
Octavian Geagla
Contact
octavian@sleepspace.com
9177571660
Daniel Taylor, PhD
study director · University of Arizona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion